Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) plus trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC).

被引：0

作者：

Planchard, David

Besse, Benjamin

Groen, Harry

Hashemi, Sayed

Mazieres, Julien

Kim, Tae Min

Quoix, Elisabeth A.

Souquet, Pierre Jean

Barlesi, Fabrice

Baik, Christina S.

Villaruz, Liza C.

Kelly, Ronan Joseph

Zhang, Shirong

Tan, Monique

Gasal, Eduard

Santarpia, Libero

Johnson, Bruce E.

机构：

[1] Inst Gustave Roussy, Thorac Team, Villejuif, France

[2] Univ Paris Sud, Gustave Roussy, Villejuif, France

[3] Univ Groningen, Groningen, Netherlands

[4] Univ Med Ctr Groningen, Groningen, Netherlands

[5] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

[6] CHU Toulouse, Hop Larrey, Toulouse, France

[7] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[8] Univ Hosp Strasbourg, Strasbourg, France

[9] Hop Jour, Pierre Benitef, France

[10] Aix Marseille Univ, AP HM, Marseille, France

[11] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[12] Univ Pittsburgh, Med Ctr, Hillman Canc Ctr, Pittsburgh, PA USA

[13] Baylor Univ, Med Ctr, Dallas, TX USA

[14] Novartis Pharmaceut, E Hanover, NJ USA

[15] Novartis Pharma AG, Basel, Switzerland

[16] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9593

引用

页数：2

共 50 条

[31] MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF DABRAFENIB PLUS TRAMETINIB VERSUS PEMBROLIZUMAB PLUS CHEMOTHERAPY IN PATIENTS WITH TREATMENT-NAIVE METASTATIC BRAF V600 MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
Tai, T. A.
Perampaladas, K.
Cooney, P.
Mensah, L.
Jameson, K.
Rafia, R.
Bains, R.
Kane, N.
VALUE IN HEALTH, 2023, 26 (12) : S49 - S49
[32] PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K-mutant metastatic melanoma (MM) who received dabrafenib plus trametinib (D plus T) in the randomized phase 3 COMBI-v study.
Schadendorf, Dirk
Long, Georgina V.
Grob, Jean Jacques
Nathan, Paul D.
Ribas, Antoni
Davies, Michael A.
Flaherty, Keith T.
Squires, Matthew
Jaeger, Savina
Powell, William
Tan, Puay
Robert, Caroline
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[33] PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K-mutant metastatic melanoma (MM) who received dabrafenib plus trametinib (D plus T) in the randomized phase 3 COMBI-v study.
Schadendorf, Dirk
Long, Georgina V.
Grob, Jean Jacques
Nathan, Paul D.
Ribas, Antoni
Davies, Michael A.
Flaherty, Keith
Squires, Matthew
Jaeger, Savina
Powell, William
Tan, Puay
Robert, Caroline
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
[34] Gefitinib with or without pemetrexed in non-squamous (NS) non-small cell lung cancer (NSCLC) with EGFR mutation (mut): Final overall survival (OS) results from a randomized phase II study
Yang, J. C-H.
Cheng, Y.
Murakami, H.
Yang, P-C.
He, J.
Nakagawa, K.
Kang, J. H.
Kim, J-H.
Wnag, X.
Enatsu, S.
Puri, T.
Orlando, M.
ANNALS OF ONCOLOGY, 2018, 29
[35] Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: Results from two phase II studies
Mitsudomi, T.
Ahn, M-J.
Bazhenova, L.
Blackhall, F.
Hida, T.
Majem Tarruella, M.
Vowler, S. L.
Laus, G.
Janne, P. A.
Yang, J. C-H.
ANNALS OF ONCOLOGY, 2017, 28
[36] Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data
Li, Junlong
Sasane, Medha
Zhang, Jie
Zhao, Jing
Ricculli, Marie Louise
Yao, Zhiwen
Redhu, Suman
Signorovitch, James
BMJ OPEN, 2018, 8 (08):
[37] Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma
Long, Georgina V.
Stroyakovskiy, Daniil
Gogas, Helen
Levchenko, Evgeny
De Braud, Filippo G.
Larkin, James M. G.
Garbe, Claus
Jouary, Thomas
Hauschild, Axel
Grob, Jean Jacques
Chiarion-Sileni, Vanna
Lebbe, Celeste
Mandala, Mario
Millward, Michael
DeMarini, Douglas James
Irani, Jhangir G.
Jin, Fan
Swann, R. Suzanne
Mookerjee, Bijoyesh
Flaherty, Keith
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[38] ANCHOR CRC: Results from a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer
Van Cutsem, E.
Taieb, J.
Yaeger, R.
Yoshino, T.
Maiello, E.
Elez, E.
Dekervel, J.
Ross, P.
Ruiz Casado, A.
Graham, J.
Kato, T.
Ruffinelli, J.
Andre, T.
Roussel, E. Carriere
Klauck, I.
Groc, M.
Grothey, A.
Vedovato, J.
Tabernero, J.
ANNALS OF ONCOLOGY, 2021, 32 : S222 - S222
[39] AURA17 study of osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC): Updated phase II results including overall survival (OS)
Zhou, C.
Wang, M.
Cheng, Y.
Chen, Y.
Zhao, Y.
Shi, Y-K.
Ahn, M-J.
Lu, Y.
Shi, M.
Han, J-Y.
Kim, S-W.
Zhang, H-L.
Chen, G.
Li, H.
Wang, J.
Wu, Y-L.
ANNALS OF ONCOLOGY, 2018, 29
[40] Phase (Ph) II safety and efficacy results of a single-arm ph ib/II study of capmatinib (INC280) + gefitinib in patients (pts) with EGFR-mutated (mut) cMET-positive (cMET plus ) non-small cell lung cancer (NSCLC).
Wu, Yi-Long
Kim, Dong-Wan
Felip, Enriqueta
Zhang, Li
Liu, Xiaoqing
Zhou, Cai Cun
Lee, Dae Ho
Han, Ji-Youn
Krohn, Alexander
Lebouteiller, Rachel
Xu, Cindy
Squires, Matthew
Akimov, Mikhail
Tan, Daniel Shao-Weng
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 3 4 5 →